Free tool
FAERS Monitor: Belsomra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204569 or its brand name (Belsomra, Suvorexant). Reports on generic versions are filed under their own applications.
Reports
13,031
Serious
4,515
35% of reports
Hospitalization
2,057
Death reported
718
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,050
- nightmare743
- somnolence738
- insomnia688
- abnormal dreams603
- headache549
- feeling abnormal489
- nausea395
- no adverse event389
- hallucination380
- fatigue365
- dizziness341
- anxiety317
- off label use275
- fall272
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 13 |
| 2015 | 2,481 |
| 2016 | 2,499 |
| 2017 | 2,016 |
| 2018 | 1,159 |
| 2019 | 926 |
| 2020 | 783 |
| 2021 | 714 |
| 2022 | 600 |
| 2023 | 602 |
| 2024 | 492 |
| 2025 | 417 |
| 2026 | 329 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal dreamsSignal | 603 | 36.0 | 33.3 | 20,070 |
| nightmareSignal | 743 | 35.4 | 33.0 | 24,309 |
| hallucinationSignal | 380 | 8.2 | 7.4 | 2,382 |
| somnolenceSignal | 738 | 5.9 | 5.5 | 3,041 |
| insomniaSignal | 688 | 4.2 | 3.9 | 1,677 |
| drug ineffectiveSignal | 3,050 | 3.7 | 3.6 | 6,519 |
| no adverse eventSignal | 389 | 3.5 | 3.1 | 686 |
| feeling abnormalSignal | 489 | 3.3 | 3.0 | 788 |
| anxiety | 317 | 1.8 | 1.6 | 113 |
| headache | 549 | 1.4 | 1.3 | 68 |
| fall | 272 | 1.3 | 1.2 | 21 |
| dizziness | 341 | 1.1 | 1.0 | 3 |
| nausea | 395 | 0.8 | 0.7 | 19 |
| fatigue | 365 | 0.8 | 0.7 | 29 |
| off label use | 275 | 0.5 | 0.5 | 137 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.